Gilead Sciences (GILD) Receivables - Other (2019 - 2021)

Gilead Sciences (GILD) has reported Receivables - Other for 3 consecutive years, with $9.0 million the latest figure, recorded in Q1 2021.

• For the quarter ending Q1 2021, Receivables - Other fell 85.0% year-over-year to $9.0 million; the trailing twelve-month figure through Mar 2021 stood at $9.0 million (down 85.0% YoY), and the FY2020 full-year result was $9.0 million, down 75.68% from the prior year.
• Receivables - Other was little changed at $9.0 million in Q1 2021 per GILD's latest filing, from $9.0 million in the prior quarter.
• Across five years, Receivables - Other topped out at $60.0 million in Q1 2020 and bottomed at $9.0 million in Q4 2020.
• Historically, Receivables - Other has averaged $36.7 million across 3 years, with a median of $43.0 million in 2019.
• The sharpest annual moves came in 2020 and 2021: Receivables - Other tumbled 75.68% in 2020, then plunged 85.0% in 2021.
• Over 3 years, Receivables - Other stood at $37.0 million in 2019, then sank by 75.68% to $9.0 million in 2020, then changed by 0.0% to $9.0 million in 2021.
• According to Business Quant data, Receivables - Other over the past three periods registered $9.0 million, $9.0 million, and $49.0 million for Q1 2021, Q4 2020, and Q3 2020 respectively.